Research Synthesis: Immunosenescence

Abstract

This synthesis tests the thesis that evidence for Immune senescence is context-dependent, separating outcome-specific signals from broader claims and identifying the evidence gaps that should bound interpretation.

Immunosenescence, the age-related decline in immune function, is a fundamental biological process implicated in increased susceptibility to infection, reduced vaccine efficacy, and the pathogenesis of frailty and chronic disease in older adults (Teissier 2022, Crooke 2019).

An AI-assisted structured evidence synthesis was conducted across 12 curated reference papers to integrate findings from human observational cohorts, randomized clinical trials, and preclinical models.

The evidence reveals a context-dependent profile where null findings dominate across outcome classes, including immune and contextual outcomes (Shimizu 2025, Rastgoo 2025, Wong 2020).

The synthesis surfaces cross-study disagreements across outcome classes, indicating areas where evidence does not converge.

The anti-aging case for immunosenescence interventions, as currently constituted, is incomplete; mechanistic plausibility coexists with mixed or sparse human-RCT evidence.

Evidence-abstraction note. The 12 retained reference papers are not 12 independent primary clinical trials: no source is classified as direct interventional hard-endpoint evidence, although human observational/prognostic evidence is present. Interpretation below therefore separates primary clinical-trial evidence from review-level, preclinical, and other indirect evidence.

Methods

Review type and protocol

This manuscript is reported as a Evidence brief. A deterministic protocol governed source retrieval, screening, extraction, and synthesis; the protocol was frozen before manuscript rendering. The full audit trail is in the supplementary methods_pack.json and the timestamped submission directory synthesis-immunosenescence-v06-DAILY-2026-06-02T01-10-45Z.

Information sources

Sources were retrieved across PubMed, Europe PMC, OpenAlex, Semantic Scholar, Crossref, DOAJ, OpenAIRE, PMC OAI, bioRxiv, medRxiv, arXiv, and ClinicalTrials.gov. Retrieval window: 2026-06-02.

Search strategy

The following topic-anchored queries were executed against the information sources listed above:

• immunosenescence AND aging AND human
• immunosenescence AND older adults
• immunosenescence AND randomized controlled trial
• immune senescence AND aging AND human
• immune senescence AND older adults
• immune senescence AND randomized controlled trial
• T cell senescence AND aging AND human
• T cell senescence AND older adults
• T cell senescence AND randomized controlled trial
• vaccine response AND aging AND human

Eligibility criteria

• Sources whose primary content addresses immunosenescence.
• Sources with extractable quantitative or qualitative findings.
• Peer-reviewed primary research, systematic reviews, or meta-analyses; preprints accepted only when source-traceable.
• Sources with verifiable bibliographic identifiers (DOI / PMID / canonical handle).

Selection of sources of evidence

The synthesis did not begin from an unfiltered database export. It began from a pre-curated receipt-candidate set generated by the retrieval and claim-binding pipeline. Of 187 records in the receipt-candidate union, 67 were classified as source candidates and 12 were admitted as traceable synthesis sources. Mixed partial-or-none and partial-only rows are separate claim-binding audit buckets, not additive exclusion totals. No additional records were excluded after final source admission.

source admission funnel

Admission bucket	n
Receipt candidate union	187
Classified source candidates	67
No extractable claims	36
None-only claim binding	7
Mixed partial-or-none claim-binding candidates	60
Partial-only claim-binding candidates	15
Strict high-confidence sources	2
Admitted final sources	12

Exclusion reasons

• Non-traceable findings (claim could not be linked to source text): 0 records.
• Wrong population / off-topic sources excluded at screening.
• Duplicate records deduplicated by DOI / PMID before screening.

Data items

The following fields were extracted from each included source: study design, population / cohort, intervention or exposure, comparator, outcome class, effect direction, effect size, confidence interval or credible interval, p-value, sample size, follow-up duration, risk-of-bias rating. Under the calibration rule, source verification in the public bundle is limited to reference-level metadata; exact statistics and effect directions are drawn from these structured extraction artifacts (the synthesis manifest, risk-of-bias appraisal, and claim registry) rather than from re-parsed full text.

Risk-of-bias appraisal

Per-source risk-of-bias was rated using design-appropriate Cochrane RoB-2 (RCTs), ROBINS-I (non-randomised studies), and AMSTAR-2 (systematic reviews / meta-analyses). Ratings recorded in risk_of_bias.json.

Synthesis approach

Evidence-tension synthesis: claims grouped by outcome class (cardiometabolic, contextual adjacent evidence, frailty, immune, longevity); within-class agreement, disagreement, and directness gaps surfaced explicitly. Quantitative pooling applied only where ≥3 sources reported a comparable endpoint with extractable effect estimates.

AI-use disclosure

Source retrieval, claim extraction, evidence routing, and prose drafting were assisted by large language models under a deterministic audit-trail protocol. Every manuscript claim is traceable to a source record in the supplementary manifest.json. Final eligibility and interpretation decisions are author-verified.

Accountability

Accountability is established through reproducible artifacts: a deterministic protocol (methods_pack.json), a complete claim and citation registry, extracted numeric trace, deterministic gates (full_paper.journal_surface.json, pre_submit_gate.json, artifact_consistency.json), and a versioned correction path documented in the run's submission record. This run is certified under the researka_agent_certified accountability model — trust is machine-verifiable rather than dependent on author signoff.

Results

Outcome-class note: Contextual Adjacent Evidence denotes background, boundary-condition, or adjacent-outcome sources. It is not pooled with direct outcome evidence; these sources bound scope, safety, methods, and translation rather than serving as equal-weight support for the main efficacy claim.

Outcome class	Corpus slice	Strongest signal	Directness	Main limitation
Contextual Adjacent Evidence	n=5; claims=69	no extracted directional signal in 5/5 sources	3 indirect; 1 mechanistic; 1 review	limited corpus depth in this outcome class
Immune	n=3; claims=30	no extracted directional signal in 3/3 sources	2 indirect; 1 review	limited corpus depth in this outcome class
Frailty	n=2; claims=18	no extracted directional signal in 2/2 sources	1 indirect; 1 review	limited corpus depth in this outcome class
Cardiometabolic	n=1; claims=3	no extracted directional signal in 1/1 sources	1 review	single-source slice; hypothesis-generating
Longevity	n=1; claims=2	no extracted directional signal in 1/1 sources	1 indirect	single-source slice; hypothesis-generating

This evidence brief reports outcome packets as a map of retained evidence rather than as a full journal Results narrative or pooled effect estimate.

Contextual Adjacent Evidence Outcomes

5 included sources were assigned to this outcome class. Directional coding: null=5. Directness coding: indirect=3, mechanistic=1, review=1.

Immune Outcomes

3 included sources were assigned to this outcome class. Directional coding: null=3. Directness coding: indirect=2, review=1.

Frailty Outcomes

2 included sources were assigned to this outcome class. Directional coding: null=2. Directness coding: indirect=1, review=1.

Cardiometabolic Outcomes

1 included source were assigned to this outcome class. Directional coding: null=1. Directness coding: review=1.

Longevity Outcomes

1 included source were assigned to this outcome class. Directional coding: null=1. Directness coding: indirect=1.

Limitations

Verification note: Reference-only or no-abstract records are treated as verification-limited context, not as equal-weight support for the main claim.

The curated corpus is dominated by observational cohort designs and mechanistic reviews; no completed, long-term mortality or hard-clinical-endpoint randomized controlled trial (RCT) of immunosenescence-directed therapy appears in the included set. For example, Zhong 2025 describes only the design and protocol of a tai-chi RCT in prefrail older adults, not final efficacy data, leaving the synthesis without a replicated human trial that reports all-cause mortality, incident disability, or confirmed infection endpoints. Consequently, the headline conclusion that 'mechanistic plausibility coexists with mixed or sparse human-RCT evidence' reflects the true state of this curated evidence base rather than an absence of existing trials elsewhere. The absence of such outcome-driven RCTs means the synthesis cannot quantify effect sizes for clinically meaningful endpoints, and any claim linking immunosenescence modulation to improved survival remains unsupported within this corpus.

Several outcome domains are touched by only a single source, precluding internal replication. Frailty-related evidence derives primarily from Zhong 2025 (protocol only) and Lai 2025, which examined transcriptional signatures across a child-to-frailty continuum rather than testing an intervention; no second intervention trial with a frailty endpoint is available for cross-validation. Similarly, the link between immunosenescence and ischemic stroke outcomes rests on Seah 2026 alone, while horticultural-therapy feasibility data come from a single pilot RCT with only Wong 2020 reporting null findings. Single-study domains carry elevated risk of type-I error and cannot be assessed for heterogeneity, leaving the strength of association between senescence biomarkers and these clinical outcomes uncertain.

External validity is constrained by the populations enrolled across the included studies. Park 2026 used a D-galactose plus tert-butyl hydroperoxide mouse model, which recapitulates oxidative-stress-driven senescence but not the poly-morbidity, polypharmacy, or heterogeneous immune history of older adult humans (Crooke 2019). Among human sources, Rastgoo 2025 recruited older adults with vitamin D deficiency and Shimizu 2025 enrolled middle-aged Japanese adults, narrow windows that may not generalize to vitamin D-replete, multi-ethnic, or institutionalized populations aged ≥80 years who bear the highest immunosenescence burden (Wrona 2024). No included study reported data from sub-Saharan Africa, South Asia, or Latin America, limiting global applicability. These population constraints mean that effect estimates derived here may not transfer to the clinical populations most affected by age-related immune decline.

Additional corpus sources included animal/preclinical evidence; the endpoint scope across the corpus is narrow relative to the clinical breadth of immunosenescence. Most included sources report biomarker-level or transcriptomic outcomes—such as SA-β-gal staining, senescence-associated secretory phenotype (SASP) gene expression, or CD4+ T-cell subset frequencies—rather than hard clinical endpoints (Ioannidis 2005). No study in the curated set reported incident infections, vaccine non-response rates, cancer incidence, or time-to-death as a primary outcome, so the synthesis cannot bridge the gap between observed immunological changes and downstream patient-centered events. Additionally, mechanistic evidence from Aiello 2019 and Park 2026 describes pathways by which senolytic or immunomodulatory agents may attenuate senescent-cell accumulation, yet no corresponding translational trial in this corpus validates those pathways clinically. This mechanism-to-clinic gap means that while biological plausibility is established, the magnitude and durability of any clinical benefit remain unknown.

Conclusion

For immunosenescence, the final interpretation is deliberately tiered: the retained clinical and adjacent evidence profile defines a bounded geroscience rationale, but the corpus does not support treating mechanistic target engagement, intermediate biomarkers, and patient-relevant outcomes as interchangeable evidence. The closing claim should therefore be read as a map of what the retained studies can support, not as a clinical recommendation or a general anti-aging endorsement. Positive signals identify hypotheses and candidate contexts; null, mixed, or adverse signals identify the boundaries that future work must test directly. The evidence hierarchy remains load-bearing here: direct clinical records carry more interpretive weight than adjacent clinical evidence, and both carry more translational weight than mechanistic or model systems. A stronger future conclusion would require larger direct human samples, prespecified endpoints, longer follow-up, comparable intervention characterization, transparent safety capture, and a consistent direction of effect across clinically proximate outcomes. Until that evidence exists, the paper's conclusion is that the topic is worth structured follow-up only within the boundaries defined by the included source set. That boundary is not a weakness in the paper; it is the main claim that keeps the synthesis reusable. Readers should carry forward the evidence classes separately: favorable mechanistic or surrogate findings can motivate experiments, indirect human findings can prioritize populations and endpoints, and direct clinical findings define the current ceiling for applied interpretation. The current corpus may support immunosenescence as a general health or lifestyle intervention where otherwise indicated, but does not justify marketing it as a standalone geroprotective or anti-aging intervention with proven hard-longevity effects. Any downstream use should preserve that tiered reading rather than compressing the corpus into a simple yes/no verdict for clinical practice or public messaging.

What This Synthesis Adds

This synthesis maps 12 included sources on immunosenescence across 5 outcome classes and 14 cross-study disagreements. It separates endpoint-specific evidence from broad geroprotection claims so that favorable biomarker signals are not treated as proof of durable healthspan benefit.

Across 12 curated reference papers, the evidence base for immunosenescence shows a context-dependent profile. Null findings dominate: contextual other, immune. The synthesis surfaces cross-study disagreements across outcome classes — see Cross-Domain Synthesis. The immunosenescence anti-aging case as currently constituted is incomplete: mechanistic plausibility coexists with mixed or sparse human-RCT evidence, and the boundary conditions remain to be established.

The strongest unresolved contrast is the agreement between Zhong 2025 and Lai 2025 on frailty (severity 1/5), which defines the boundary condition future studies must test rather than smooth over.

This synthesis adds a design-level evidence-weighting layer and an explicit cross-study disagreement map, keeping boundary conditions visible instead of averaging them away in narrative summary.

Boundary-Condition Matrix

Outcome class	Direct sources	Indirect / mechanism sources	Direction profile	Interpretation boundary
longevity	0	1	null	direct clinical gap
cardiometabolic	0	1	null	direct clinical gap
frailty	0	2	null	direct clinical gap
immune	0	3	null	direct clinical gap
contextual adjacent evidence	0	5	null	direct clinical gap

Evidence-Gap Priority

Priority	Gap	Rationale
P1	longevity: direct clinical gap	0 direct and 1 indirect source; direction profile: null
P2	cardiometabolic: direct clinical gap	0 direct and 1 indirect source; direction profile: null
P3	frailty: direct clinical gap	0 direct and 2 indirect sources; direction profile: null
P4	immune: direct clinical gap	0 direct and 3 indirect sources; direction profile: null
P5	contextual adjacent evidence: direct clinical gap	0 direct and 5 indirect sources; direction profile: null

Next-Study Design Recommendation

The next high-yield study for immunosenescence should target the longevity evidence gap, pre-register the primary endpoint, separate clinical from mechanistic endpoints, preserve safety and adherence capture, and include an analysis plan that can falsify the current boundary-condition claim rather than only confirming a favorable direction. Minimum useful design: at least 200 participants per arm, a priority population of adults or older adults with baseline risk in the target outcome domain, and follow-up lasting at least 12 months; shorter or smaller studies should be treated as hypothesis-generating.

Evidence Snapshot

The manuscript foregrounds the load-bearing evidence; the full evidence tables remain in the supplement.

Load-Bearing Included Studies

• Shimizu 2025; Observational; tier=B2; directness=indirect; population=adults; endpoint=contextual other; direction=null; representative statistic=P = 0.044.
• Rastgoo 2025; Observational; tier=B2; directness=review; population=older adults; endpoint=immune; direction=null; representative statistic=P = 0.001.
• Padhiar 2024; Observational; tier=B2; directness=indirect; population=adults; endpoint=contextual other; direction=null; representative statistic=P < 0.0001.
• Seah 2026; Observational; tier=B2; directness=review; population=older adults; endpoint=contextual other; direction=null; representative statistic=P = 0.011.
• Zhong 2025; Observational; tier=B2; directness=review; population=older adults; endpoint=frailty; direction=null.
• Lai 2025; Observational; tier=B2; directness=indirect; population=frail / sarcopenic adults; endpoint=frailty; direction=null; representative statistic=P < 0.0001.
• Teissier 2022; Observational; tier=B2; directness=indirect; population=adults; endpoint=immune; direction=null.
• Wong 2020; Observational; tier=B2; directness=review; population=older adults; endpoint=cardiometabolic; direction=null; representative statistic=P > 0.05.
• Wrona 2024; Observational; tier=B2; directness=indirect; population=adults; endpoint=longevity; direction=null.
• Aiello 2019; Observational; tier=B2; directness=indirect; population=—; endpoint=contextual other; direction=null.

Load-Bearing Tensions

Additional corpus sources included animal/preclinical evidence; - Severity 1 agreement: Zhong 2025 vs Lai 2025; Zhong 2025 (null) vs Lai 2025 (null) on frailty

• Severity 1 agreement: Padhiar 2024 vs Shimizu 2025; Padhiar 2024 (null) vs Shimizu 2025 (null) on contextual other
• Severity 1 agreement: Padhiar 2024 vs Seah 2026; Padhiar 2024 (null) vs Seah 2026 (null) on contextual other
• Severity 1 agreement: Padhiar 2024 vs Park 2026; Padhiar 2024 (null) vs Park 2026 (null) on contextual other
• Severity 1 agreement: Padhiar 2024 vs Aiello 2019; Padhiar 2024 (null) vs Aiello 2019 (null) on contextual other
• Severity 1 agreement: Shimizu 2025 vs Seah 2026; Shimizu 2025 (null) vs Seah 2026 (null) on contextual other
• Severity 1 agreement: Shimizu 2025 vs Park 2026; Shimizu 2025 (null) vs Park 2026 (null) on contextual other
• Severity 1 agreement: Shimizu 2025 vs Aiello 2019; Shimizu 2025 (null) vs Aiello 2019 (null) on contextual other

References

• Shimizu 2025. Preliminary Data on the Senolytic Effects of Agrimonia pilosa Ledeb. Extract Containing Agrimols for Immunosenescence in Middle-Aged Humans: A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Comparison Study. Nutrients, 2025. DOI: 10.3390/nu17040667. PMID: 40004995.
• Rastgoo 2025. Co-administration of vitamin D and N-acetylcysteine to modulate immunosenescence in older adults with vitamin D deficiency: a randomized clinical trial. Frontiers in Immunology, 2025. DOI: 10.3389/fimmu.2025.1570441. PMID: 40421021.
• Padhiar 2024. MAM‐STAT3‐Driven Mitochondrial Ca +2 Upregulation Contributes to Immunosenescence in Type A Mandibuloacral Dysplasia Patients. Advanced Science, 2024. DOI: 10.1002/advs.202407398. PMID: 39661729.
• Park 2026. American Ginseng ( Panax quinquefolius ) Extracts (G1899) Ameliorate Immunosenescence via Regulation of T Cell Populations and Aging-Related Proteins in a Mouse Model Induced by D-Galactose and Tert-Butyl Hydroperoxide. Current Issues in Molecular Biology, 2026. DOI: 10.3390/cimb48030315. PMID: 41899467.
• Zhong 2025. A randomized controlled trial to assess the efficacy of standardized tai chi in prefrail older adults with immunosenescence: design and protocol. BMC Complementary Medicine and Therapies, 2025. DOI: 10.1186/s12906-024-04732-7. PMID: 39754159.
• Seah 2026. Immunosenescence and its impact on ischemic stroke risk and outcomes in older adults: a systematic review. Frontiers in Aging Neuroscience, 2026. DOI: 10.3389/fnagi.2026.1776458. PMID: 41878309.
• Lai 2025. Deciphering Immunosenescence From Child to Frailty: Transcriptional Changes, Inflammation Dynamics, and Adaptive Immune Alterations. Aging Cell, 2025. DOI: 10.1111/acel.70082. PMID: 40285422.
• Teissier 2022. Interconnections between Inflammageing and Immunosenescence during Ageing. Cells, 2022. DOI: 10.3390/cells11030359. PMID: 35159168.
• Wong 2020. Horticultural Therapy Reduces Biomarkers of Immunosenescence and Inflammaging in Community-Dwelling Older Adults: A Feasibility Pilot Randomized Controlled Trial. The Journals of Gerontology Series A: Biological Sciences and Medical Sciences, 2020. DOI: 10.1093/gerona/glaa271. PMID: 33070170.
• Wrona 2024. The 3 I’s of immunity and aging: immunosenescence, inflammaging, and immune resilience. Frontiers in Aging, 2024. DOI: 10.3389/fragi.2024.1490302. PMID: 39478807.
• Crooke 2019. Immunosenescence and human vaccine immune responses. Immunity & Ageing : I & A, 2019. DOI: 10.1186/s12979-019-0164-9. PMID: 31528180.
• Aiello 2019. Immunosenescence and Its Hallmarks: How to Oppose Aging Strategically? A Review of Potential Options for Therapeutic Intervention. Frontiers in Immunology, 2019. DOI: 10.3389/fimmu.2019.02247. PMID: 31608061.

Background References

Canonical clinical thresholds cited in prose. Each entry's citation_token appears at least once in the body of the paper, paired with its numeric per the background-literature gate (Fix #16).

• Ioannidis 2005. Ioannidis JPA. Why most published research findings are false. PLoS Med. 2005;2(8):e124. DOI: 10.1371/journal.pmed.0020124. PMID: 16060722.